The 2018 European Society for Medical Oncology (#ESMO18) Congress will take place in Munich from October 19 to 23 and it’s a meeting we’re looking forward to covering on Biotech Strategy Blog.

We’ll have “boots on the ground” in Munich.

ESMO 2018 Banner

One of the highlights of the ESMO Congress are the late-breaking abstracts, for which ESMO keeps open multiple slots in their program. As a result, the meeting provides an opportunity to hear some of the latest data.

The titles and times for most of the late-breakers have now been published in the on line program, so what can we look forward to at ESMO18?

In our first Preview we’ve highlighted several to watch out for, why we think they are noteworthy and in many cases, what the potential significance might be in a broader context.

Please note that the abstracts for late breakers aren’t typically available until the start of the congress session in which they will be presented or if they’re in the press program, until after the press briefing, so we’re not discussing any data in this post.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by